Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Glixogen Therapeutics
Glixogen Therapeutics Overview
Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS).
Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease.
Glixogen Therapeutics was founded at the FutuRx biotechnology incubator.